16353-5 |
Amino beta guanidinopropionate |
PrThr |
Urine |
Pt |
Ord |
|
|
ACTIVE |
Amino beta guanidinopropionate [Presence] in Urine |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
16353-5 |
|
|
|
|
Both |
|
|
|
0 |
AB-Gp Ur Ql |
|
|
|
|
|
AB-Gp; Amino beta guanidinopropionic acid; Amino betaguanidinopropionate; Aminobetaguanidinopropionate; B; Chemistry; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; UA; UR; Urn |
2.56 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
16354-3 |
Amino beta guanidinopropionate |
MCnc |
Urine |
Pt |
Qn |
|
|
DEPRECATED |
Deprecated Amino beta guanidinopropionate [Mass/volume] in Urine |
|
DEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
16354-3 |
|
|
|
|
|
|
|
|
0 |
Deprecated AB-Gp Ur-mCnc |
|
|
|
|
|
AB-Gp; Amino beta guanidinopropionic acid; Amino betaguanidinopropionate; Aminobetaguanidinopropionate; B; Chemistry; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.36 |
1.0l |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
16355-0 |
Amino beta guanidinopropionate |
PrThr |
Plas |
Pt |
Ord |
|
|
ACTIVE |
Amino beta guanidinopropionate [Presence] in Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
16355-0 |
|
|
|
|
Both |
|
|
|
0 |
AB-Gp Plas Ql |
|
|
|
|
|
AB-Gp; Amino beta guanidinopropionic acid; Amino betaguanidinopropionate; Aminobetaguanidinopropionate; B; Chemistry; Ordinal; Pl; Plasma; Plsm; Point in time; PR; QL; Qual; Qualitative; Random; Screen |
2.56 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
16356-8 |
Amino beta guanidinopropionate |
MCnc |
Plas |
Pt |
Qn |
|
|
DEPRECATED |
Deprecated Amino beta guanidinopropionate [Mass/volume] in Plasma |
|
DEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
16356-8 |
|
|
|
|
|
|
|
|
0 |
Deprecated AB-Gp Plas-mCnc |
|
|
|
|
|
AB-Gp; Amino beta guanidinopropionic acid; Amino betaguanidinopropionate; Aminobetaguanidinopropionate; B; Chemistry; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.36 |
1.0l |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
16357-6 |
Amino beta guanidinopropionate |
MCnc |
CSF |
Pt |
Qn |
|
|
DEPRECATED |
Deprecated Amino beta guanidinopropionate [Mass/volume] in Cerebral spinal fluid |
|
DEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
16357-6 |
|
|
|
|
|
|
|
|
0 |
Deprecated AB-Gp CSF-mCnc |
|
|
|
|
|
AB-Gp; Amino beta guanidinopropionic acid; Amino betaguanidinopropionate; Aminobetaguanidinopropionate; B; Cerebral spinal fluid; Cerebrospinal Fl; Chemistry; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid |
2.36 |
1.0l |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
16358-4 |
Amino beta guanidinopropionate |
MCnc |
Amnio fld |
Pt |
Qn |
|
|
DEPRECATED |
Deprecated Amino beta guanidinopropionate [Mass/volume] in Amniotic fluid |
|
DEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
16358-4 |
|
|
|
|
|
|
|
|
0 |
Deprecated AB-Gp Amn-mCnc |
|
|
|
|
|
AB-Gp; AF; Amino beta guanidinopropionic acid; Amino betaguanidinopropionate; Aminobetaguanidinopropionate; Amn; Amn fl; Amnio; Amniotic flu; Amniotic fluid; B; Chemistry; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.36 |
1.0l |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
16359-2 |
Amiodarone+Desethylamiodarone |
MCnc |
Ser |
Pt |
Qn |
|
|
DEPRECATED |
Deprecated Amiodarone+Desethylamiodarone [Mass/volume] in Serum or Plasma |
|
DEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
16359-2 |
|
|
|
|
|
|
|
|
0 |
Deprecated Amiodarone+Deseth Ser-mCnc |
|
|
|
|
|
Amiodarone metabolite; Cordarone; DEA; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Noramiodarone; Pacerone; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SR |
2.36 |
1.0l |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
1636-0 |
Somatotropin^pre 250 ug L-Dopa TID 2day PO |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Somatotropin [Mass/volume] in Serum or Plasma --pre 250 ug L-dopa TID 2day PO |
|
MIN |
DefinitionDescription |
|
|
ug/L;ng/mL |
|
|
|
|
|
|
CHAL |
|
1636-0 |
|
|
|
|
Observation |
|
|
|
0 |
GH pre 250 ug L-D TID 2D PO SerPl-mCnc |
|
|
|
Y |
|
Before; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; GH; Growth hormone; HGH; Human growth hormone; Left; Level; Levo; Mass concentration; mcg; Pl; Plasma; Plsm; Point in time; pre 250 ug L-D TID 2D PO; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; Somatotropic hormone; SR; STH; three times a day |
2.4 |
1 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
16360-0 |
Amitriptyline^peak |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Amitriptyline [Mass/volume] in Serum or Plasma --peak |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
16360-0 |
|
|
|
|
Both |
|
|
|
0 |
Amitrip Peak SerPl-mCnc |
|
|
|
Y |
|
Amit; Amitrip; Amitriptylene; Amitriptyln; DRUG/TOXICOLOGY; Drugs; Elatrol; Elavil; Endep; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; Post; Postdose; Post-dose; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Trepiline; Tryptanol; Tryptizol |
2.4 |
1.0l |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
16361-8 |
Amitriptyline^trough |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Amitriptyline [Mass/volume] in Serum or Plasma --trough |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
16361-8 |
|
|
|
|
Both |
|
|
|
0 |
Amitrip Trough SerPl-mCnc |
|
|
|
Y |
|
Amit; Amitrip; Amitriptylene; Amitriptyln; DRUG/TOXICOLOGY; Drugs; Elatrol; Elavil; Endep; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; Pre; Predose; Pre-dose; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Trepiline; Tryptanol; Tryptizol |
2.4 |
1.0l |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
16362-6 |
Ammonia |
SCnc |
Plas |
Pt |
Qn |
|
|
ACTIVE |
Ammonia [Moles/volume] in Plasma |
|
MIN |
DefinitionDescription |
|
|
umol/L |
|
|
|
|
|
|
CHEM |
|
16362-6 |
|
|
|
|
Both |
|
|
|
0 |
Ammonia Plas-sCnc |
|
|
|
Y |
|
Amm; Ammon; Amon; Chemistry; Hepatology; Kidney; Level; Liver; Nephrology; NH3; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; Renal; Substance Concentration; UniversalLabOrders |
2.73 |
1.0l |
|
|
|
|
|
|
|
umol/L |
|
|
|
185 |
16363-4 |
Ammonia |
SCnt |
Tiss |
Pt |
Qn |
|
|
ACTIVE |
Ammonia [Moles/mass] in Tissue |
|
MIN |
DefinitionDescription |
|
|
umol/g |
|
|
|
|
|
|
CHEM |
|
16363-4 |
|
|
|
|
Both |
|
|
|
0 |
Ammonia Tiss-sCnt |
|
|
|
Y |
|
Amm; Ammon; Amon; Chemistry; Hepatology; Kidney; Liver; Nephrology; NH3; Point in time; QNT; Quan; Quant; Quantitative; Random; Renal; Substance Content; Tissue; Tissue, unspecified |
2.42 |
1.0l |
|
|
|
|
|
|
|
umol/g |
|
|
|
0 |
16364-2 |
Amobarbital |
MCnc |
Gast fld |
Pt |
Qn |
|
|
ACTIVE |
Amobarbital [Mass/volume] in Gastric fluid |
|
MIN |
DefinitionDescription |
|
|
ug/mL |
|
|
|
|
|
|
DRUG/TOX |
|
16364-2 |
|
|
|
|
Both |
|
|
|
0 |
Amobarbital Gast-mCnc |
|
|
|
Y |
|
Addiction; Amobarb; Amylobarbitone; Amytal; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; GAST; Gastric contents; Gastric fluid; Illicit; Level; Mass concentration; Point in time; PotentialForAbuse; QNT; Quan; Quant; Quantitative; Random |
2.42 |
1.0l |
|
|
|
|
|
|
|
ug/mL |
|
|
|
0 |
16365-9 |
Amoxicillin+Clavulanate |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
DEPRECATED |
Deprecated Amoxicillin+Clavulanate [Mass/volume] in Serum or Plasma |
|
DEL |
DefinitionDescription |
|
|
ug/mL |
|
|
|
|
|
|
DRUG/TOX |
|
16365-9 |
|
|
|
|
Both |
|
|
|
0 |
Deprecated Amoxicillin+Clav SerPl-mCnc |
|
|
|
Y |
|
Amox; Amoxicillin+clavulanic acid; Amoxicilloyl; Amoxil; Augmentin; Bristamox; c204; c305; c6; Clav; Clavate; Clavu; Clavul; Clavulanic; Clavulanic acid; DRUG/TOXICOLOGY; Drugs; Larotid; Level; Mass concentration; Moxalin; Moxicillin+clavulanic acid; Pl; Plasma; Plsm; Point in time; Polymox; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Sumox; Trimox; Wymox |
2.65 |
1.0l |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
16366-7 |
Diethylpropion |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Diethylpropion [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
DRUG/TOX |
|
16366-7 |
|
|
|
|
Both |
|
|
|
0 |
Diethylpropion SerPl-mCnc |
|
|
|
Y |
|
Addiction; Amphepramone; Diethylprop; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Illicit; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; PotentialForAbuse; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Tenuate |
2.34 |
1.0l |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
16367-5 |
Amphetamine/Methamphetamine |
MCrto |
Urine |
Pt |
Ord |
|
|
DEPRECATED |
Deprecated Amphetamine/Methamphetamine [Mass ratio] in Urine Qualitative |
|
DEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
16367-5 |
|
|
|
|
Both |
|
|
|
0 |
Deprecated Amphet/Methamphet Ur |
|
|
|
|
|
Amph; Amphet; Amphet+Methamphet; Amphetam; Amphetamines; Ampht; Desoxyn; DRUG/TOXICOLOGY; Drugs; Methamphet; Ordinal; Point in time; QL; Qual; Qualitative; Random; Screen; Speed; UA; UR; Urn |
2.4 |
1.0l |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
16369-1 |
Amphetamines |
PrThr |
Urine |
Pt |
Ord |
Confirm |
|
ACTIVE |
Amphetamines [Presence] in Urine by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
16369-1 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Amphetamines Ur Ql Cfm |
|
|
|
|
|
Addiction; Amph; Amphetam; Amphetamine; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; GCMS; Illicit; LC/MS/MS; Ordinal; Point in time; PotentialForAbuse; PR; QL; Qual; Qualitative; Random; Screen; Speed; UA; UR; Urn |
2.73 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect new model for ordinal terms; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
1637-8 |
Somatotropin^pre dose insulin IV |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Somatotropin [Mass/volume] in Serum or Plasma --pre dose insulin IV |
|
MIN |
DefinitionDescription |
|
|
ug/L;ng/mL |
|
|
|
|
|
|
CHAL |
|
1637-8 |
|
|
|
|
Observation |
|
|
|
0 |
GH pre Ins IV SerPl-mCnc |
|
|
|
Y |
|
Before; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; GH; Growth hormone; HGH; HUM; Human growth hormone; Humulin; IH7; Insul; Lente; Level; Mass concentration; NPH; Pl; Plasma; Plsm; Point in time; pre Ins IV; QNT; Quan; Quant; Quantitative; Random; Semilente; SerP; SerPl; SerPlas; Serum; Serum or plasma; Sliding; Somatotropic hormone; SR; STH; Ultralente |
2.4 |
1 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
16370-9 |
Amphotericin B |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Amphotericin B [Mass/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
ug/mL |
|
|
|
|
|
|
DRUG/TOX |
|
16370-9 |
|
|
|
|
Both |
|
|
|
0 |
Amphotericin B Ur-mCnc |
|
|
|
Y |
|
DRUG/TOXICOLOGY; Drugs; Fungizone; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.42 |
1.0l |
|
|
|
|
|
|
|
ug/mL |
|
|
|
0 |
16373-3 |
Amyl ether |
PrThr |
Bld |
Pt |
Ord |
|
|
ACTIVE |
Amyl ether [Presence] in Blood |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
16373-3 |
|
|
|
|
Both |
|
|
|
0 |
Amyl ether Bld Ql |
|
|
|
|
|
Blood; DRUG/TOXICOLOGY; Drugs; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; WB; Whole blood |
2.56 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect the new model for ordinal terms where results are based on a cut-off value.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
16374-1 |
Amyl nitrite |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Amyl nitrite [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
16374-1 |
|
|
|
|
Both |
|
|
|
0 |
Amyl nitrite SerPl-mCnc |
|
|
|
Y |
|
DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; NO2; Pl; Plasma; Plsm; Point in time; Poppers; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.34 |
1.0l |
|
|
|
|
|
|
|
|
|
|
|
0 |
16378-2 |
Androstenedione^2nd specimen post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Androstenedione [Mass/volume] in Serum or Plasma --2nd specimen post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
ng/dL |
|
|
|
|
|
|
CHAL |
|
16378-2 |
|
|
|
|
Observation |
|
|
|
0 |
Androst sp2 p chal SerPl-mCnc |
|
|
|
Y |
|
After; CHEMISTRY.CHALLENGE TESTING; Convalescent; gamma-4-Androstenedione; Level; Mass concentration; p chal; Pl; Plasma; Plsm; Point in time; Post immunization; PST; QNT; Quan; Quant; Quantitative; Random; Second; SerP; SerPl; SerPlas; Serum; Serum or plasma; sp2; sp2 p chal; Spec; SR |
2.73 |
1.0l |
|
|
|
|
|
|
|
ng/dL |
|
|
|
0 |
16379-0 |
Androstenedione^3rd specimen post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Androstenedione [Mass/volume] in Serum or Plasma --3rd specimen post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
ng/dL |
|
|
|
|
|
|
CHAL |
|
16379-0 |
|
|
|
|
Observation |
|
|
|
0 |
Androst sp3 p chal SerPl-mCnc |
|
|
|
Y |
|
After; CHEMISTRY.CHALLENGE TESTING; gamma-4-Androstenedione; Level; Mass concentration; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; sp3; sp3 p chal; Spec; SR |
2.73 |
1.0l |
|
|
|
|
|
|
|
ng/dL |
|
|
|
0 |
1638-6 |
Testosterone^96H post 5000 U HCG IM |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Testosterone [Mass/volume] in Serum or Plasma --96 hours post 5000 U HCG IM |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
CHAL |
|
1638-6 |
|
|
|
|
Observation |
|
|
|
0 |
Testost 96h p 5000 U HCG IM SerPl-mCnc |
|
|
|
Y |
|
96h p 5000 U HCG IM; After; CHEMISTRY.CHALLENGE TESTING; Chorionic gonadotropin stimulation test; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Testo; Testos; Testost |
2.34 |
1 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
16380-8 |
Androstenedione^4th specimen post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Androstenedione [Mass/volume] in Serum or Plasma --4th specimen post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
ng/dL |
|
|
|
|
|
|
CHAL |
|
16380-8 |
|
|
|
|
Observation |
|
|
|
0 |
Androst sp4 p chal SerPl-mCnc |
|
|
|
Y |
|
After; CHEMISTRY.CHALLENGE TESTING; gamma-4-Androstenedione; Level; Mass concentration; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; sp4; sp4 p chal; Spec; SR |
2.34 |
1.0l |
|
|
|
|
|
|
|
ng/dL |
|
|
|
0 |